Clinical trialPhase 1 / Phase 2Completed
Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer
- Outcome
- Finished, no results posted
- Phase
- Phase 1 / Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- June 2004
- Expected end
- February 2010
- Enrollment
- 40 participants
- Sites
- 1
- Primary outcomes
- Occurrence of dose limiting toxicity up to three weeks following the second cycle of chemotherapy.
- Sponsor
- Other
- Results posted
- No
- Last update
- 15 November 2010
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study will examine a proposed research treatment which evaluates the addition of oxaliplatin, a chemotherapy agent, to gemcitabine, another chemotherapy agent, and radiation therapy for the treatment of patients with pancreatic cancer. The researchers have already done studies using gemcitabine and radiation therapy together. They want to build on the information they have from this previous research. The researchers believe that the combination chemotherapy with radiation is worth investigating to treat pancreatic cancer. They will use this study to determine what type of side effects occur with this treatment and to assess how effective the treatment is at controlling the cancer.